title: FDA OK's two drugs for irritable bowel syndrome. The arsenal of IBS drugs is growing, but diagnosis is tricky.
authors.affiliation: Section of Gastroenterology, Temple University Hospital, Philadelphia, Pennsylvania, USA.
authors.forename: Brenda J
authors.initials: BJ
authors.lastname: Horwitz
mesh_terms: D002243:Carbolines / Q000627:therapeutic use*; D003109:Colonic Diseases, Functional / Q000175:diagnosis / Q000188:drug therapy*; D003937:Diagnosis, Differential; D017277:Drug Approval; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D002243:Carbolines; D005765:Gastrointestinal Agents; D007211:Indoles; C090840:alosetron; C105050:tegaserod